Drugs Containing Excipient (Inactive Ingredient) TREHALOSE DIHYDRATE

« Back to Dashboard

Branded drugs containing TREHALOSE DIHYDRATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Liquidia Technologies Inc	YUTREPIA	treprostinil	72964-011	TREHALOSE DIHYDRATE	2037-05-05
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	TREHALOSE DIHYDRATE	2033-11-15

Generic drugs containing TREHALOSE DIHYDRATE excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme Corp	trastuzumab	0006-5033	TREHALOSE DIHYDRATE
Novartis Pharmaceuticals Corporation	secukinumab	0078-0639	TREHALOSE DIHYDRATE
GlaxoSmithKline LLC	belantamab	0173-0896	TREHALOSE DIHYDRATE
GlaxoSmithKline LLC	depemokimab	0173-0927	TREHALOSE DIHYDRATE
AstraZeneca Pharmaceuticals LP	benralizumab	0310-1730	TREHALOSE DIHYDRATE

Last updated: September 26, 2026

Executive summary: Trehalose dihydrate is a pharmaceutical excipient with demand tied primarily to biologics stabilization, lyophilized injectables, vaccines, cell and gene therapy, and specialty formulations. Its commercial value is driven by formulation performance rather than dose volume. The market has favorable structural growth but remains price-sensitive, supplier-concentrated, and difficult to quantify because manufacturers rarely report trehalose revenue separately. Patent risk is generally low for the excipient itself; the principal barriers are grade qualification, GMP manufacturing, regulatory documentation, supply continuity, and formulation-specific intellectual property.

Trehalose Dihydrate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is trehalose dihydrate used for in pharmaceutical formulations?

Trehalose dihydrate is the crystalline dihydrate form of trehalose, a nonreducing disaccharide composed of two glucose units. Its CAS number is 6138-23-4. Pharmaceutical manufacturers use it as a stabilizer, lyoprotectant, cryoprotectant, bulking agent, tonicity modifier, and carrier in selected dosage forms.

Attribute	Trehalose dihydrate
Chemical name	α,α-Trehalose dihydrate
Common CAS number	6138-23-4
Primary pharmaceutical role	Stabilizer and lyoprotectant
Typical applications	Injectable biologics, vaccines, lyophilized products, ophthalmics, cell and gene therapy formulations
Physical form	Crystalline powder
Key performance property	Stabilizes proteins and membranes during freezing and drying
Regulatory classification	Pharmaceutical excipient, not an active pharmaceutical ingredient
Main alternatives	Sucrose, mannitol, sorbitol, lactose, glycine, amino acids, polysorbates

Trehalose forms hydrogen-bonding interactions with proteins and lipid membranes. During freeze-drying, it can replace some of the water associated with biomolecular structures and reduce aggregation or structural damage. It also has a relatively low tendency to participate in Maillard reactions compared with reducing sugars such as lactose.

The excipient is particularly relevant where a formulation must maintain biologic activity after freezing, drying, transport, or reconstitution. Its use is less compelling in conventional immediate-release tablets, where lower-cost fillers and binders often meet performance requirements.

What pharmaceutical products create demand for trehalose dihydrate?

Demand is concentrated in complex and temperature-sensitive products rather than high-volume oral medicines.

Biologics and monoclonal antibodies

Protein therapeutics are a major demand source. Trehalose may be included in liquid or lyophilized formulations to reduce aggregation, particle formation, and potency loss. Formulation selection depends on the protein, concentration, pH, buffer system, surfactant, container closure, and storage temperature.

Use in biologics is commercially attractive because excipient cost is small relative to the value of the drug product. A manufacturer may accept a higher unit price for a qualified excipient if changing the stabilizer would require substantial formulation development, comparability work, and regulatory filing activity.

Vaccines

Trehalose is used in some vaccine and biologic stabilization systems. Its value increases where products require cold-chain protection or must tolerate freeze-drying. Demand is affected by vaccine production volumes, public-health procurement, and platform technology choices.

Cell and gene therapy

Cell and gene therapy creates a high-value, lower-volume opportunity. Trehalose can be used in cryopreservation and stabilization systems for cells, viral vectors, and other advanced therapy components. The addressable volume per product may be modest, but qualification requirements and switching costs can be high.

Ophthalmic and specialty formulations

Trehalose is used in some ophthalmic products, including dry-eye and ocular-surface formulations. These products may use trehalose for osmoprotection and surface stabilization. Ophthalmic demand is less dependent on biologics manufacturing but is exposed to consumer health competition and formulation substitution.

Oral solid dosage forms

Trehalose can function as a sweetener, diluent, or stabilizer in oral products, but this is generally a smaller commercial opportunity than injectable and biologic applications. Cost and hygroscopicity considerations can favor mannitol, lactose, sucrose, or other excipients.

How large is the pharmaceutical trehalose dihydrate market?

No standardized public dataset isolates pharmaceutical-grade trehalose dihydrate revenue from food, cosmetic, laboratory, and industrial trehalose. Commercial market reports use different definitions and often combine all trehalose applications. Public-company filings generally do not disclose trehalose sales as a separate line item.

The most defensible market view is therefore segment-based:

Market segment	Demand outlook	Commercial characteristics
Biologics formulation	Strong	High switching costs and high value per kilogram
Lyophilized injectables	Strong	Dependent on sterile manufacturing and freeze-drying pipelines
Vaccines	Moderate to strong	Volume can rise sharply during procurement cycles
Cell and gene therapy	Strong from a small base	High qualification burden and specialized requirements
Ophthalmic products	Moderate	Fragmented demand and competition from other osmoprotectants
Oral solid dosage	Low to moderate	Price-sensitive and readily substitutable
Food and nutrition	Separate major market	Can affect manufacturing scale and raw-material economics

The pharmaceutical market is likely to grow faster than mature food applications because biologics, injectable products, and advanced therapies continue to expand. The growth rate is unlikely to translate directly into supplier revenue because manufacturers can reformulate, reduce trehalose concentration, or substitute sucrose and mannitol where product performance permits.

What are the main drivers of trehalose dihydrate demand?

The strongest demand drivers are:

1. Growth in biologic drug approvals and commercial production.
2. Expansion of lyophilized injectable pipelines.
3. Increasing use of temperature-sensitive vaccines and advanced therapies.
4. Greater focus on protein aggregation, particulate control, and shelf life.
5. Outsourcing of formulation, fill-finish, and biologics manufacturing to contract development and manufacturing organizations.
6. Adoption of higher-purity excipients with stronger documentation packages.
7. Increased use of cell-processing and cryopreservation technologies.

FDA guidance for biologic products places substantial emphasis on product quality, stability, and control of manufacturing inputs. An excipient does not need to be novel to become commercially important. It must be consistent, appropriately characterized, and suitable for the intended formulation and route of administration (U.S. Food and Drug Administration [FDA], 1997).

Which companies supply pharmaceutical-grade trehalose dihydrate?

The supply chain includes specialist excipient producers, carbohydrate manufacturers, distributors, and formulation-service companies. Hayashibara, part of Nagase, is one of the best-known commercial trehalose producers. Other suppliers and distributors may offer pharmaceutical-grade or compendial material depending on jurisdiction and product specification.

Supplier evaluation should focus on the exact grade rather than the corporate name. Key diligence points include:

Qualification area	Commercial relevance
USP-NF or Ph. Eur. compliance	Reduces customer qualification burden
GMP manufacturing	Required for regulated pharmaceutical use
Bioburden and endotoxin controls	Critical for parenteral products
Residual solvent and impurity profile	Supports regulatory filings
Water content and solid-state form	Affects stability and processing
Batch-to-batch consistency	Reduces formulation and filling risk
Audit history and change control	Limits supply disruption and filing exposure
Dual-site or backup capacity	Improves continuity of supply
DMF or regulatory support	Accelerates customer submissions

Food-grade trehalose cannot automatically be substituted for pharmaceutical-grade material. The issue is not only purity. Pharmaceutical customers also assess manufacturing controls, traceability, deviation handling, analytical methods, and change-notification procedures.

What is the financial trajectory for trehalose dihydrate suppliers?

Trehalose dihydrate has an attractive margin profile in qualified pharmaceutical applications but a mixed volume profile.

Revenue growth should come from higher pharmaceutical penetration, increased biologics production, and expansion of advanced therapies. Gross-margin performance depends on crystallization yield, drying and milling costs, packaging, testing, compliance infrastructure, and utilization of manufacturing assets.

Revenue trajectory

Period	Expected market condition	Financial effect
Near term	Continued biologics and injectable demand; cautious inventory management	Moderate volume growth, uneven ordering
Medium term	More lyophilized biologics and cell-processing applications	Higher pharmaceutical-grade demand and qualification revenue
Longer term	Broader use in advanced therapy logistics and stabilization	Stronger mix, but competition from alternative excipients

Supplier revenue is likely to be more volatile than end-market demand. Customers may build inventory before regulatory submissions, then reduce purchases during clinical delays or commercial destocking. A single biologic formulation change can remove a recurring order, while a successful product launch can create multi-year demand.

Margin trajectory

Pharmaceutical-grade trehalose generally commands a premium over food-grade material because of testing, documentation, controlled manufacturing, and customer qualification. Margins can improve when:

• pharmaceutical volumes increase relative to food volumes;
• suppliers sell directly to drug manufacturers rather than through distributors;
• customers commit to long-term supply agreements;
• manufacturing capacity is efficiently utilized;
• the supplier provides formulation, regulatory, or analytical support.

Margins can deteriorate when customers compare trehalose against lower-cost sucrose or mannitol, when food-market oversupply pressures pricing, or when energy and packaging costs rise.

Public filings generally do not provide sufficient information to calculate standalone trehalose revenue, EBITDA, or operating margin for individual suppliers. Financial exposure is best assessed through product mix, pharmaceutical customer concentration, manufacturing capacity, and the share of sales generated from qualified grades.

How does trehalose compare with sucrose, mannitol, and other excipients?

Trehalose competes on stability and formulation performance, not simply price.

Excipient	Main advantage	Main limitation relative to trehalose
Sucrose	Low cost and broad regulatory familiarity	Can be less suitable in some stability systems; reducing-sugar concerns do not apply, but formulation-specific degradation remains relevant
Mannitol	Strong bulking agent and crystalline cake former	May provide less stabilization of some proteins and membranes
Sorbitol	Useful liquid-phase stabilizer and tonicity modifier	Hygroscopicity and formulation-specific stability concerns
Lactose	Low cost and established oral-use profile	Reducing sugar; less suitable for some protein formulations
Glycine	Useful bulking and buffering contribution	Can promote crystallization or interact with specific proteins
Trehalose	Strong stabilization and cryoprotection profile	Higher cost and more limited supplier base

Trehalose often works in combination with mannitol or other excipients. Mannitol can improve the physical structure of a lyophilized cake, while trehalose provides greater amorphous stabilization. The balance depends on collapse temperature, glass-transition temperature, reconstitution time, residual moisture, and protein stability.

What is the FDA regulatory status of trehalose dihydrate?

Trehalose has a long history of food use and appears in FDA materials concerning food safety and excipient use. FDA’s GRAS Notice Inventory includes trehalose-related notices, including GRN 91, which addressed trehalose for food uses (FDA, n.d.-a).

For pharmaceutical use, regulatory acceptance is product-specific. A manufacturer must demonstrate that the excipient is suitable for the route, dose, formulation, and manufacturing process. FDA’s Inactive Ingredient Database can support assessment of prior use in approved drug products, but database listing does not guarantee acceptance in a new product or route (FDA, n.d.-b).

Important regulatory considerations include:

• compendial specification and test methods;
• identity of the dihydrate form;
• water content and hydrate stability;
• microbial limits;
• endotoxin controls for parenteral use;
• elemental impurities;
• residual solvents;
• container-closure compatibility;
• supplier change-control procedures.

Trehalose dihydrate is not itself an approved active drug and does not receive drug exclusivity.

What is the Orange Book status of trehalose dihydrate?

Trehalose dihydrate does not have an Orange Book patent estate as an excipient. The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information for those products (FDA, n.d.-c).

The practical consequences are:

• there is no standalone Orange Book listing for trehalose dihydrate;
• there is no trehalose-specific New Drug Application exclusivity period;
• there is no Paragraph IV challenge directed solely to trehalose as an excipient;
• patents may still cover a finished drug formulation that contains trehalose;
• a generic or biosimilar applicant may challenge formulation or method-of-use patents involving trehalose through the applicable product pathway.

What patents protect trehalose dihydrate formulations?

The trehalose molecule and basic trehalose dihydrate composition are old and generally not a strong platform for new composition-of-matter exclusivity. Commercial patent value is more likely to reside in:

• specific biologic formulations containing trehalose;
• defined trehalose-to-protein ratios;
• lyophilized cakes with specified residual moisture;
• combinations of trehalose, surfactants, buffers, and amino acids;
• cryopreservation media;
• ophthalmic formulations;
• vaccine stabilization systems;
• manufacturing methods that control crystallinity or hydrate conversion;
• container-closure and reconstitution systems.

Patent term for a U.S. utility patent generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and regulatory patent-term extension rules (35 U.S.C. §154). The expiry date must be determined patent by patent.

How strong is the patent estate for trehalose dihydrate?

The excipient-level estate is weak to moderate because the core molecule is established and widely used. Formulation-level estates can be stronger when they claim a narrow stability window or a difficult-to-reproduce combination of excipients and process parameters.

Patent strength depends on:

1. claim breadth;
2. enablement across multiple proteins or products;
3. evidence of unexpected stability benefits;
4. freedom-to-operate around alternative sugars;
5. remaining patent term;
6. prosecution history;
7. whether claims cover the commercial product or only a narrow laboratory formulation.

For a biosimilar, trehalose-related patents are more likely to create formulation or process litigation risk than molecule-level blocking rights.

What generic, biosimilar, and manufacturing risks exist?

Generic entry risk

Generic entry risk is low for trehalose itself because it is an excipient rather than a drug product. The risk becomes relevant when a finished injectable or ophthalmic product relies on trehalose-containing formulation claims.

Biosimilar risk

Biosimilar developers may face patents covering a reference biologic’s formulation, lyophilization cycle, stabilizer system, or container. Trehalose can be one element in those claims. The commercial effect depends on whether the biosimilar can use sucrose, mannitol, or another stabilizer without compromising comparability and manufacturability.

Manufacturing and supply risk

The principal barriers are operational:

• limited number of qualified pharmaceutical suppliers;
• dependence on specific fermentation or enzymatic production routes;
• crystallization and drying consistency;
• hydrate-form control;
• long customer qualification cycles;
• regulatory impact of supplier or site changes;
• logistics costs for low-volume, high-documentation products.

A supply interruption can affect a drug manufacturer disproportionately because replacing the excipient may require formulation studies, stability data, process validation, and regulatory notification.

What licensing deals and litigation affect trehalose dihydrate?

Publicly disclosed licensing transactions centered solely on trehalose dihydrate are limited. Commercial relationships are more likely to involve supply agreements, distribution arrangements, formulation partnerships, or broader biologics technology licenses in which trehalose is an ancillary excipient.

There is no general trehalose-specific litigation framework comparable to patent disputes involving blockbuster active ingredients. Disputes are more likely to concern:

• proprietary biologic formulations;
• excipient supplier quality;
• product liability;
• change-control obligations;
• supply interruptions;
• confidential manufacturing processes;
• formulation patent enforcement by the finished-drug sponsor.

How should investors assess trehalose dihydrate exposure?

The most useful indicators are not commodity volume alone. Investors and corporate-development teams should examine:

Indicator	Why it matters
Pharmaceutical-grade share of sales	Indicates pricing power
Number of qualified drug-product customers	Measures concentration risk
Exposure to commercial biologics	Separates recurring demand from development demand
DMF and regulatory support capability	Indicates customer lock-in
Dual-source status	Shows supply resilience
Capacity utilization	Affects margin leverage
Share of revenue from food applications	Signals commodity-price exposure
Patent-protected formulation applications	Indicates defensibility
Long-term supply contracts	Improves revenue visibility
Customer change-control history	Measures switching friction

The strongest business model combines pharmaceutical-grade manufacturing, regulatory support, direct relationships with biologics companies, and a diversified customer base. A producer competing mainly on bulk trehalose price is more exposed to substitution and food-market cycles.

Key Takeaways

• Trehalose dihydrate is a high-value excipient used mainly in biologics, vaccines, lyophilized injectables, ophthalmics, and advanced therapies.
• Its demand outlook is favorable because biologic and temperature-sensitive products are expanding.
• Standalone market size and supplier revenue are difficult to quantify because public reporting combines pharmaceutical, food, cosmetic, and industrial trehalose.
• Pharmaceutical-grade material commands a premium because of GMP controls, testing, documentation, and qualification requirements.
• The excipient itself has limited patent protection; formulation, process, and finished-product patents create the main IP risks.
• Trehalose has no standalone Orange Book listing, drug exclusivity period, or Paragraph IV pathway.
• Sucrose and mannitol remain the principal substitutes, with the choice determined by protein stability, cake structure, cost, and process requirements.
• Financial performance depends more on pharmaceutical mix and qualified customer relationships than on total trehalose volume.
• Supply continuity, hydrate-form control, batch consistency, and regulatory change management are the main manufacturing barriers.

FAQs About Trehalose Dihydrate

Is trehalose dihydrate safe for injectable drug products?

It can be used in injectable formulations when the specific grade, dose, route, impurity profile, microbial controls, and formulation are adequately justified to regulators. Prior use does not eliminate product-specific qualification requirements.

Is trehalose dihydrate the same as trehalose anhydrous?

No. Trehalose dihydrate contains two waters of crystallization, while anhydrous trehalose does not. The forms can differ in water content, solid-state behavior, processing performance, and stability.

Can sucrose replace trehalose dihydrate in a biologic formulation?

Sometimes, but not automatically. Substitution requires formulation screening, stability testing, process assessment, and potentially regulatory comparability work.

Does trehalose dihydrate require a Drug Master File?

A DMF is not universally mandatory. Suppliers may maintain a DMF or provide equivalent regulatory documentation to support customer submissions and quality assessments.

Is trehalose dihydrate a commodity excipient?

Food-grade trehalose can behave as a commodity product. Pharmaceutical-grade trehalose dihydrate is less commoditized because GMP production, documentation, qualification, and supply continuity influence purchasing decisions.

References

1. U.S. Food and Drug Administration. (1997). Guidance for industry: Drug product manufacturing controls for biological products. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.-a). GRAS notice inventory. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices
3. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
5. U.S. Patent Act, 35 U.S.C. §154. (2024). Contents and term of patent; provisional rights. https://uscode.house.gov/ |